Premium
When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents
Author(s) -
Adişen E.,
Karaca F.,
Gürer M. A.
Publication year - 2008
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.2007.02673.x
Subject(s) - etanercept , efalizumab , psoriasis , medicine , psoriatic arthritis , biological drugs , dermatology , intensive care medicine , plaque psoriasis , rheumatoid arthritis
Summary Guidelines and treatment strategies for the new biological agents have been developed, but dermatologists continue to face difficulties in adopting these guidelines into their daily practices. We report a patient with psoriasis and psoriatic arthritis whose skin lesions responded only to efalizumab, and the arthritis to etanercept. This case shows that different biological agents may achieve different success rates even in the same patient. Each biological agent offers different advantages and disadvantages, which sometimes make it difficult to choose the single best agent for a patient. Psoriasis often becomes one of the most difficult diseases to treat and does not respond to any single antipsoriatic agent. Perhaps in the future, rotational or combination treatment with different biological treatments will be used.